Meningococcal Vaccines: Menveo vs. Bexsero
Menveo and Bexsero protect against different meningococcal serogroups: Menveo (MenACWY) covers serogroups A, C, W, and Y, while Bexsero (MenB-4C) specifically protects against serogroup B disease. 1
Key Differences Between the Vaccines
Menveo (MenACWY-CRM)
- Serogroup coverage: A, C, W-135, and Y only 1
- Does NOT protect against serogroup B 1
- Technology: Conjugate vaccine using polysaccharides linked to CRM197 (mutant diphtheria toxin) 2
- Licensed for: Ages 2 months through 55 years 1
Bexsero (MenB-4C)
- Serogroup coverage: B only 3
- Does NOT protect against A, C, W, or Y
- Technology: Four-component protein-based vaccine with recombinant proteins plus outer membrane vesicles 4, 5
- Licensed for: Ages 10-25 years 3
- Dosing: 2-dose series (now can be given 6 months apart for healthy adolescents 16-23 years) 6
Critical Clinical Point
These vaccines are NOT interchangeable—they target completely different disease-causing strains. 7 A 16-year-old needs assessment for BOTH vaccine types, as they serve distinct protective roles.
Routine Vaccines Due for a 16-Year-Old Female
At age 16, this patient is due for a MenACWY booster dose (if her first dose was given before age 16) and should receive shared clinical decision-making counseling about MenB vaccination. 8, 7
Meningococcal Vaccination Algorithm for This Patient
1. MenACWY (Menveo or Menactra) - ROUTINE
- If she received her first MenACWY dose at age 11-15: Give booster NOW at age 16 8
- If she received her first dose at age 16 or later: No booster needed 8
- If never vaccinated: Give first dose now, no booster required 8
2. MenB (Bexsero or Trumenba) - SHARED CLINICAL DECISION
Age 16-23 years (preferred 16-18) qualifies for MenB vaccination based on shared clinical decision-making, NOT routine recommendation. 3, 7
- Discuss with patient/family: Short-term protection against serogroup B disease (which causes 40% of meningococcal cases in this age group) 9
- Risk factors to emphasize: College residence hall living, outbreak settings, complement deficiencies, asplenia 3
- If choosing Bexsero: 2 doses separated by 6 months 6
- If choosing Trumenba: 2 doses at 0 and 6 months (or 3-dose series for high-risk) 3
- Critical: The two MenB products are NOT interchangeable—must complete series with same product 7
3. HPV Vaccine
- Verify completion status: Should have completed 2-dose series (if started before age 15) or 3-dose series (if started at 15 or later) 7
- If incomplete: Complete the series now
4. Tdap Booster
- Verify she received Tdap at age 11-12 9
- If not: Administer now as catch-up
5. Annual Influenza Vaccine
- Due annually 10
6. COVID-19 Vaccine
- Verify up-to-date status per current 2024-2025 recommendations 6
Practical Implementation Notes
Both MenACWY and MenB can be given during the same visit using different injection sites. 7 This is particularly relevant at age 16 when the MenACWY booster is due and MenB discussion is optimal.
Common Pitfall to Avoid
Do not assume that because a patient received "meningococcal vaccine" at age 11-12, they are fully protected. Serogroup B requires separate vaccination and is NOT included in routine MenACWY. 9 Many families are unaware of this distinction.
Documentation Checklist
- Date of first MenACWY dose (determines booster need)
- HPV series completion status
- Tdap administration at age 11-12
- Discussion of MenB shared clinical decision-making
- Annual vaccines (influenza, COVID-19) current status
The MenB recommendation is Category B (permissive, based on shared clinical decision-making), while MenACWY booster at 16 is Category A (routine recommendation). 3 This distinction matters for counseling and insurance coverage.